Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC

Introduction: In a phase 1 study, bintrafusp alfa was found to have an encouraging clinical activity in patients with previously treated advanced NSCLC. This study evaluated the safety and efficacy of bintrafusp alfa with chemotherapy in patients with stage IV NSCLC regardless of the programmed deat...

Full description

Saved in:

Bibliographic Details
Main Authors:	Christian Rolfo, MD, PhD, Laurent Greillier, MD, PhD, Remi Veillon, MD, PhD, Firas Badin, MD, MBA, Francois Ghiringhelli, MD, PhD, Nicolas Isambert, MD, PhD, Astrid Paulus, MD, PhD, Surendra Pal Chaudhary, MD, Yulia Vugmeyster, PhD, Masashi Sato, MSc, Sandrine Hiret, MD, PhD
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	JTO Clinical and Research Reports
Subjects:	Bintrafusp alfa TGF-β Bifunctional Stage IV Non–small cell lung cancer
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666364324001188
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC

Similar Items